Several Axl inhibitors and monoclonal antibodies target the extracellular domains, kinase domains, or ligands of Axl [30, 33, 35, 36]; however, the inherent challenges these types of inhibitors pose; such as inability to recognize tumor cells with mutant ligands may be mitigated by CDK9’s transcriptional regulation of Axl, thus improving the impact of targeting Axl-mediated resistance to therapy. Here, AXL is linked to neoplasm.